Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
1. An isolated monoclonal antibody which comprises a heavy chain variable domain and a light chain variable domain, wherein said heavy chain comprises 3 CDRs and said light chain comprises 3 CDRs, wherein the sequences of said CDRs of said antibody are selected from the group consisting of:
(a) SEQ ID NOs: 18, 26, 32 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(b) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(c) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 20, 27, 36 of the LC,
(d) SEQ ID NOs: 18, 26, 37 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(e) SEQ ID NOs: 18, 26, 38 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(f) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(g) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 21, 27, 33 of the LC,
(h) SEQ ID NOs: 18, 28, 39 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(i) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 22, 27, 33 of the LC,
(j) SEQ ID NOs: 18, 26, 32 of the HC plus SEQ ID NOs: 22, 27, 33 of the LC,
(k) SEQ ID NOs: 18, 29, 39 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(l) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 23, 27, 33 of the LC,
(m) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 20, 27, 40 of the LC,
(n) SEQ ID NOs: 18, 26, 32 of the HC plus SEQ ID NOs: 21, 27, 33 of the LC,
(o) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 24, 27, 33 of the LC,
(p) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 21, 27, 33 of the LC,
(q) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 23, 27, 33 of the LC,
(r) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 20, 30, 33 of the LC,
(s) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 25, 27, 33 of the LC,
(t) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 20, 30, 33 of the LC,
(u) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 20, 27, 40 of the LC, and
(v) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 20, 31, 33 of the LC; wherein said antibody specifically binds to at least one of Ang1 and Ang2 ligands of Tie 2 receptor.
2. The isolated antibody of claim 1 , wherein said antibody is an IgG.
3. The isolated antibody of claim 1 that is a fully human antibody.
4. An antigen binding fragment of the antibody of claim 1 .
5. An isolated nucleic acid molecule encoding the antibody of claim 1 or the antigen binding fragment of claim 4 .
6. A vector containing the nucleic acid molecule of claim 5 .
7. An isolated host cell containing the vector of claim 6 .
8. The host cell of claim 7 that is a CHO cell.
9. A method of making the antibody of claim 2 which comprises introducing into a host cell at least one nucleic acid molecule encoding said antibody and expressing said at least one nucleic acid molecule in the host cell.
10. The method of claim 9 wherein said host cell is a CHO cell.
11. A pharmaceutical composition comprising the antibody of claim 2 in admixture with a pharmaceutically acceptable carrier therefor.
12. The pharmaceutical composition of claim 11 further comprising a molecule selected from the group consisting of a reporter molecule, a water soluble polymer, an antibody Fc region, and a cytotoxic agent.
13. The pharmaceutical composition of claim 12 , wherein said pharmaceutically acceptable carrier is a pharmaceutical formulation agent.
14. An isolated monoclonal antibody that specifically binds to at least one of Ang1 and Ang2 ligands of Tie 2 receptor, wherein said antibody comprises a heavy chain variable domain and a light chain variable domain selected from the group consisting of:
(a) a heavy chain variable domain comprising SEQ ID NO: 1 and a light chain comprising SEQ ID NO: 12;
(b) a heavy chain variable domain comprising SEQ ID NO: 2 and a light chain comprising SEQ ID NO: 12;
(c) a heavy chain variable domain comprising SEQ ID NO: 3 and a light chain comprising a sequence selected from SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17;
(d) a heavy chain variable domain comprising SEQ ID NO: 4 and a light chain comprising a sequence selected from SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13;
(e) a heavy chain variable domain comprising SEQ ID NO: 5 and a light chain comprising SEQ ID NO: 12;
(f) a heavy chain variable domain comprising SEQ ID NO: 6 and a light chain comprising SEQ ID NO: 12; and
(g) a heavy chain variable domain comprising SEQ ID NO: 7 and a light chain comprising a sequence selected from SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16.
15. The isolated antibody of claim 1 , further comprising an IgG heavy constant domain and an IgG light chain constant domain.
16. An isolated monoclonal antibody which comprises a heavy chain variable domain and a light chain variable domain, wherein said heavy chain variable domain comprises 3 CDRs having the sequences given in SEQ ID NOs: 18, 26, 35 and said light chain variable domain comprises 3 CDRs having the sequences given in SEQ ID NOs: 23, 27, 33, wherein said antibody specifically binds to at least one of Ang1 and Ang2 ligands of Tie 2 receptor.
17. An isolated monoclonal antibody that specifically binds to at least one of Ang1 and Ang2 ligands of Tie 2 receptor, wherein said antibody comprises a heavy chain variable domain having the sequence given in SEQ ID NO: 3 and a light chain variable domain having the sequence given in SEQ ID NO: 10.
18. The isolated antibody of claim 16 or 17 , wherein said antibody is an IgG.
19. The isolated antibody of claim 16 or 17 , wherein said antibody is an IgG1.
20. The isolated antibody of claim 16 or 17 that is a fully human antibody.
21. An antigen binding fragment of the antibody of claim 16 .
22. An isolated nucleic acid molecule encoding the antibody of claim 16 or 17 , or the antigen binding fragment of claim 21 .
23. A vector containing the nucleic acid molecule of claim 22 .
24. An isolated host cell containing the vector of claim 23 .
25. The host cell of claim 24 that is a CHO cell.
26. A method of making the antibody of claim 18 which comprises introducing into a host cell at least one nucleic acid molecule encoding said antibody and expressing said at least one nucleic acid molecule in the host cell.
27. The method of claim 26 wherein said host cell is a CHO cell.
28. A pharmaceutical composition comprising the antibody of claim 18 in admixture with a pharmaceutically acceptable carrier therefor.